CD38 checkpoint inhibitor (OmniAb/Talem)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD38 checkpoint inhibitor (OmniAb/Talem)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsCheckpoint kinase inhibitors
TargetsCheckpoint kinaseLymphocyte differentiation antigen CD38
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOmniAb Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOmniAb IncTalem Therapeutics LLC
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A